Pieris Pharmaceuticals

$2.78
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-1.06%) Today
-$0.02 (-0.71%) As of 12:20 PM UTC after-hours

Why Robinhood?

You can buy or sell PIRS and other stocks, options, and ETFs commission-free!

About PIRS

Pieris Pharmaceuticals, Inc. Common Stock, also called Pieris Pharmaceuticals, is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA. The listed name for PIRS is Pieris Pharmaceuticals, Inc. Common Stock.

CEO
Stephen S. Yoder
Employees
127
Headquarters
Boston, Massachusetts
Founded
2001
Market Cap
144.53M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
731.28K
High Today
$3.01
Low Today
$2.70
Open Price
$2.78
Volume
688.67K
52 Week High
$3.64
52 Week Low
$1.60

PIRS Earnings

-$0.28
-$0.19
-$0.09
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 11, Pre-Market

You May Also Like

QRTEB
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure